Our findings reinforce studies in humans that have identified CCR2 and CD44 as being increased in NASH patients and they establish a possible link between these two molecules in lipid mediated hepatitis progression in so far as Ccr2−/− mice are largely protected from CD44 mediated HA binding [6], [7], [20]. The gene discussed is CCR2; the disease is metabolic dysfunction-associated steatohepatitis.